CME: Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Panel Update

April 2020 | Volume 19 | Issue 4 | Supplement Individual Articles | 35 | Copyright © April 2020

Published online March 20, 2020

Michael S. Kaminer , Sue Ellen Cox , Steven Fagien , Joely Kaufman , Mary P. Lupo , Ava Shamban

aDepartment of Dermatology, Yale School of Medicine, New Haven, CT bDepartment of Dermatology, Brown Medical School, Providence, RI cSkin Care Physicians, Inc, Chestnut Hill, MA dAesthetic Solutions PA, Chapel Hill, NC eSteven Fagien MD, Boca Raton, FL fSkin Associates of South Florida/Skin Research Institute, Coral Gables, FL gLupo Center for Aesthetic and General Dermatology, New Orleans, LA hAVA MD, SKIN FIVE, Los Angeles, CA

11. Bonati LM, Fabi SG. Treating the young aesthetic patient: evidence-based recommendations. J Drugs Dermatol. 2017;16(6 Suppl):S81-3.
12. Narurkar V, Shamban A, Sissins P, et Stonehouse A, Gallagher C. Facial treatment preferences in aesthetically aware women. Dermatol Surg. 2015;41(Suppl 1):S153-60.
13. American Society of Plastic Surgeons. 2018 Plastic Surgery Statistics Report. Available from: Statistics/2018/plastic- surgery-statistics-full-report-2018.pdf.  Accessed December 27, 2019.
14. Sundaram H, Liew S, Signorini M, et al. Global aesthetics consensus: hyaluronic acid fillers and botulinum toxin type a-recommendations for combined treatment and optimizing outcomes in diverse patient populations. Plast Reconstr Surg. 2016;137(5):1410-23.
15. Dover JS, Monheit G, Greener M, Pickett A. Botulinum toxin in aesthetic medicine: myths and realities. Dermatol Surg. 2018;44(2):249-60.
16. de Almeida AR, da Costa Marques ER, Banegas R, Kadunc BV. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment. Dermatol Surg. 2012;38(9):1506-15.
17. Lupo MP. Tox outside the box: off-label aesthetic uses of botulinum toxin. J Drugs Dermatol. 2016;15(9):1151-7.
18. Scaglione F. Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. Toxins (Basel). 2016;8(3).
19. Wilson AJ, Chang B, Taglienti AJ, et al. A quantitative analysis of onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA: a randomized, double-blind, prospective clinical trial of comparative dynamic strain reduction. Plast Reconstr Surg. 2016;137(5):1424-33.
20. Jeuveau [highlights of prescribing information] Santa Barbara, CA: Evolus; 2/2019.
21. Botox Cosmetic [highlights of prescribing information] Irvine, CA: Allergan, Inc.; 10/2017.
22. Xeomin [highlights of prescribing Information] Raleigh, NC: Merz Pharmaceuticals, LLC; 7/2018.
23. Dysport [highlights of prescribing information] Fort Worth, TX: Galderma Laboratories, L.P.; 1/2019.
24. Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol. 2018;11:273-87.
25. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227-41.
26. Lorenc ZP, Kenkel JM, Fagien S, et al. Consensus panel’s assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics. Aesthet Surg J. 2013;33(1 Suppl):35S-40S.
27. Maas C, Kane AC, Bucay VW, et al. Current aesthetic use of abobotulinumtoxinA in clinical practice: an evidence-based consensus review. Aesthet Surg J. 2012;32(1 Suppl):8S-29S.
28. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005;6(3):141-50.
29. Gart MS, Gutowski KA. Aesthetic uses of neuromodulators: current uses and future directions. Plast Reconstr Surg. 2015;136(5 Suppl):62S-71S.
30. Beer KR, Shamban AT, Avelar RI, Gross JE, Jonker A. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatol Surg. 2019;45(11):1381-93.
31. Wieder JM, Moy RL. Understanding botulinum toxin. Surgical anatomy of the frown, forehead, and periocular region. Dermatol Surg. 1998;24(11):1172-4.
32. Shamban A. Customized approach to facial enhancement. Facial Plast Surg Clin North Am. 2015;23(4):471-7.
33. Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. Adv Dermatol. 1997;12:325-47.
34. Kane MA, Cox SE, Jones D, Lei X, Gallagher CJ. Heterogeneity of crow’s feet lines patterns in clinical trial subjects. Dermatol Surg. 2015;41(4):447-56.
35. Carruthers A, Bruce S, de Coninck A, Connolly S, et al. Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatol Surg. 2014;40:1181-90.
36. Moers-Carpi M, Carruthers J, Fagien S, Lupo M, et al. Efficacy and safety of onabotulinumtoxinA for treating crow’s feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatol Surg. 2015;41:102-12.
37. Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanism of action. Arq Neuropsiquiatr. 2005;63(1):180-5.
38. Carruthers A, Carruthers J, Monheit GD, Davis PG, Tardie G. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/mL smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatol Surg. 2010;36(Suppl 4):2121-34.
39. Kane M, Donofrio L, Ascher B, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel’s assessment and recommendations. J Drugs Dermatol. 2010;9(1 Suppl):S7-S22.
40. Benedetto AV. What’s new in cosmetic dermatology. Dermatol Clin. 2019;37(1):117-28.
41. Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg. 1999;103(2):645-52.
42. Carruthers JD, Glogau RG, Blitzer A, Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies–consensus recommendations. Plast Reconstr Surg. 2008;121(5 Suppl):5S–30S.
43. Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA in the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.
44. Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. [Epub ahead of print]. 2019 Nov 15.
45. Jankovic J, Truong D, Patel AT, et al. Injectable daxibotulinumtoxinA in cervical dystonia: a phase 2 dose escalation multicenter study. Mov Discord Clin Pract. 2018;5(3):273-82.
46. Yoelin SG, Dhawan SS, Vitarella D, Ahmad W, Hasan F, Abushakra S. Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study. Plast Reconstr Surg. 2018;142(6):847e-55e.
47. NCT02939326. Evaluate safety and efficacy of a single treatment cycle of EB-001 in subjects with glabellar frown lines. Last updated February 15, 2019. Available at: Accessed December 27, 2019.
48. NCT03346902. Study of EB-001 in facial scar reduction. Last updated January 8, 2019. Accessed November 22, 2019. Available at: https://clinicaltrials. gov/ct2/show/NCT03346902. Accessed December 27, 2019.
49. NCT03193593. Study to evaluate EB-001 in reducing musculoskeletal pain. Last updated January 25, 2019. Available at: show/NCT03193593. Accessed December 27, 2019.
50. NCT03429556. Study to evaluate botulinum neurotoxin serotype E (EB- 001) in reducing musculoskeletal pain in abdominoplasty. Last updated February 15, 2019. Available at: NCT03429556. Accessed December 27, 2019.


Michael S. Kaminer MD